Drug profile · INN
diatrizoate meglumine
SINOGRAFIN
diatrizoate meglumine (SINOGRAFIN) is a diagnostic agent. Route of administration: urethral. Current US regulatory status: approved.
Drug details — diatrizoate meglumine
- US status
- approved
- Class
- —
- Route
- URETHRAL
- Patents
- 0
- Programs
- 3
- Data quality
- 0.84
Quick answer
diatrizoate meglumine (SINOGRAFIN) is a diagnostic agent. Route of administration: urethral. Current US regulatory status: approved.
Key facts
Mechanism of action
Diagnostic agent
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Frequently asked questions
What is diatrizoate meglumine?
diatrizoate meglumine (SINOGRAFIN) is a diagnostic agent. Route of administration: urethral. Current US regulatory status: approved.
What is the brand name for diatrizoate meglumine?
SINOGRAFIN is a marketed brand name for diatrizoate meglumine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of diatrizoate meglumine?
diatrizoate meglumine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.